Relugolix, Estradiol, Norethindrone Acetate (40mg+1.0mg+0.5mg), Oral Combination Therapy for Uterine Fibroids (Relugolix) in Premenstrual Women: A Quality Life Perspective

Abstract

The following article elucidates the role of oral therapy for uterine fibroids in increasing the quality of life and a better treatment option as compared to the conventional methods, which are operative and may result in infertility. Uterine fibroids are non-cancerous growths (myomas or leiomyomas) also known as Uterine Leiomyomas or Fibromyomas appear in or around the uterus. They can shrink after menopause, exist in adults of reproductive age, and have been connected to oestrogen, however the specific origin is unknown. Uterine fibroids affect about 1 in 3 women, and their prevalence rises with age until menopause, peaking in the forties. In general, symptoms can be categorized as heavy and protracted menstrual bleeding, pelvic pain, and reproductive dysfunction. The triple combination drug is given orally to the patients (once daily as early as possible after menstrual cycle but no later than seven days after menstrual cycle begins) and it can be given for the period of 24 months which is longer duration than its other alternatives like leuprolide (6-12 months) and it effectively resolves Abnormal Uterine Bleeding – Leiomyomata (AUB-L). It will resolve the imbalance of estrogen and progesterone in female body and reduces the side effects such as bone loss due to estrogen imbalance. Being an oral tablet gives it an advantage over other surgical procedures and parenteral dosage forms as it is non-invasive and easy to administer, in small dose, once daily. Keywords: Uterine Fibroids, Health Related Quality of Life, Gonadotropin Releasing Hormone Receptor Antagonist, Combination Therapy, Relugolix.